- Oops!Something went wrong.Please try again later.
GAITHERSBURG, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021.
Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the second quarter 2021 financial results and provide a business update.
Conference Call Information:
Wednesday, August 11
8:30 am Eastern Time
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
Investor and Media Contact:
Chief Financial Officer